Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines (Nasdaq: PRAX) announced on March 4, 2026 that its Compensation Committee granted restricted stock unit awards covering 2,931 shares to fourteen new non-executive employees under the 2024 Inducement Plan.

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) announced on March 4, 2026 that its Compensation Committee granted restricted stock unit awards covering 2,931 shares to fourteen new non-executive employees under the 2024 Inducement Plan.

The awards were granted on March 2, 2026 as inducements under Nasdaq Listing Rule 5635(c)(4) and vest in four equal annual installments, subject to continued employment on each vesting date.

Argus Mar 5 session

-4.47% close to close Open Argus

Details

News Market Reaction – PRAX

In the Mar 5 session, PRAX declined 4.47%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine equity compensation: an aggregate of 2,931 restricted stock units ...

Analysis

This announcement details routine equity compensation: an aggregate of 2,931 restricted stock units granted to 14 new non‑executive employees under the 2024 Inducement Plan, vesting in four equal annual installments. It follows a prior inducement grant in early February and comes against a backdrop of recent NDAs, leadership additions, and strong cash levels. Investors may watch how ongoing hiring and equity awards intersect with future clinical and regulatory milestones already highlighted in recent filings.

Key Figures

Inducement RSUs granted: 2,931 shares Employees receiving awards: 14 employees Vesting schedule: 4 annual installments

Inducement RSUs granted

2,931 shares

Aggregate restricted stock units granted on March 2, 2026

Employees receiving awards

14 employees

New non-executive hires under 2024 Inducement Plan

Vesting schedule

4 annual installments

RSUs vest over four equal annual installments

Historical Context

5 past events · Latest: Feb 19

5 events

1. Feb 19

   Earnings and update

   24h Move

   +0.8%

   Q4/FY 2025 results with two NDAs, strong cash and funding runway.

2. Feb 09

   Earnings date, conferences

   24h Move

   +0.3%

   Scheduled earnings release and participation in two investor conferences.

3. Feb 04

   Inducement equity grants

   24h Move

   +0.8%

   RSU awards of 2,964 shares to eight new non-executive employees.

4. Jan 13

   Leadership appointment

   24h Move

   +6.3%

   Appointment of renowned epilepsy leader as Head of Clinical Strategy.

5. Jan 12

   Strategic outlook

   24h Move

   -4.4%

   Outlined 2026 priorities with late-stage successes and large peak revenue potential.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock unit, nasdaq listing rule 5635(c)(4), inducement plan

3 terms

restricted stock unit financial

"granted restricted stock unit awards covering an aggregate of 2,931 shares of its common"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

nasdaq listing rule 5635(c)(4) regulatory

"as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan)."

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
LifeSci Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Praxis (PRAX) grant on March 2, 2026?

Praxis granted restricted stock units covering 2,931 shares to fourteen new non-executive employees. According to the company, the grants were made under the 2024 Inducement Plan as inducements tied to new hires per Nasdaq Rule 5635(c)(4).

Why did Praxis (PRAX) use the 2024 Inducement Plan for these awards?

The 2024 Inducement Plan is designated for equity awards to new hires or those returning after non-employment. According to the company, the plan was used to issue inducement awards material to individuals entering employment under Nasdaq Listing Rule 5635(c)(4).

How do the restricted stock units granted by Praxis (PRAX) vest?

The restricted stock units vest in four equal annual installments, subject to continued employment on each vesting date. According to the company, vesting requires the employee to remain employed with Praxis through each annual vesting milestone.

How many employees received inducement RSU grants from Praxis (PRAX)?

Fourteen new non-executive employees received the restricted stock unit grants. According to the company, the aggregate award covers 2,931 shares and was intended as material inducements for these hires on March 2, 2026.

Does the Praxis (PRAX) announcement reference Nasdaq Listing Rule 5635(c)(4)?

Yes. The company expressly cited Nasdaq Listing Rule 5635(c)(4) as the basis for granting inducement awards to new employees. According to the company, the grants comply with that rule and were made under the 2024 Inducement Plan.

Will the RSU grants to Praxis (PRAX) employees immediately affect shareholder dilution?

The announcement lists an aggregate of 2,931 shares in RSUs but does not quantify dilution percentage. According to the company, awards were granted under the 2024 Inducement Plan; investors must compare shares to total outstanding to assess dilution impact.